Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $9.0 million.

  • Regenxbio's Share-based Compensation fell 896.4% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.7 million, marking a year-over-year decrease of 410.37%. This contributed to the annual value of $38.5 million for FY2024, which is 448.01% down from last year.
  • Per Regenxbio's latest filing, its Share-based Compensation stood at $9.0 million for Q3 2025, which was down 896.4% from $8.7 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Share-based Compensation registered a high of $11.2 million during Q1 2023, and its lowest value of $8.3 million during Q4 2023.
  • Moreover, its 5-year median value for Share-based Compensation was $9.7 million (2021), whereas its average is $9.7 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 2373.71% in 2021, then plummeted by 1431.38% in 2024.
  • Quarter analysis of 5 years shows Regenxbio's Share-based Compensation stood at $9.2 million in 2021, then increased by 2.69% to $9.4 million in 2022, then decreased by 11.37% to $8.3 million in 2023, then increased by 14.44% to $9.5 million in 2024, then decreased by 5.7% to $9.0 million in 2025.
  • Its Share-based Compensation was $9.0 million in Q3 2025, compared to $8.7 million in Q2 2025 and $8.5 million in Q1 2025.